GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Quince Therapeutics Inc (NAS:QNCX) » Definitions » Market Cap

QNCX (Quince Therapeutics) Market Cap : $90.20 Mil (As of Dec. 11, 2024)


View and export this data going back to 2019. Start your Free Trial

What is Quince Therapeutics Market Cap?

Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Quince Therapeutics's share price for the quarter that ended in Sep. 2024 was $0.7762. Quince Therapeutics's Shares Outstanding (EOP) for the quarter that ended in Sep. 2024 was 43.28 Mil. Therefore, Quince Therapeutics's market cap for the quarter that ended in Sep. 2024 was $33.59 Mil.

Quince Therapeutics's quarterly market cap declined from Mar. 2024 ($45.81 Mil) to Jun. 2024 ($32.46 Mil) but then increased from Jun. 2024 ($32.46 Mil) to Sep. 2024 ($33.59 Mil).

Quince Therapeutics's annual market cap declined from Dec. 2021 ($379.54 Mil) to Dec. 2022 ($23.03 Mil) but then increased from Dec. 2022 ($23.03 Mil) to Dec. 2023 ($45.12 Mil).

Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Quince Therapeutics's Enterprise Value for Today is $54.29 Mil.


Quince Therapeutics Market Cap Historical Data

The historical data trend for Quince Therapeutics's Market Cap can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Quince Therapeutics Market Cap Chart

Quince Therapeutics Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Market Cap
Get a 7-Day Free Trial 1,508.45 820.71 379.54 23.03 45.12

Quince Therapeutics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Market Cap Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 40.70 45.12 45.81 32.46 33.59

Competitive Comparison of Quince Therapeutics's Market Cap

For the Biotechnology subindustry, Quince Therapeutics's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Quince Therapeutics's Market Cap Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Quince Therapeutics's Market Cap distribution charts can be found below:

* The bar in red indicates where Quince Therapeutics's Market Cap falls into.



Quince Therapeutics Market Cap Calculation

Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.

Quince Therapeutics's Market Cap for the fiscal year that ended in Dec. 2023 is calculated as

Market Cap (A: Dec. 2023 )=Share Price (A: Dec. 2023 )*Shares Outstanding (EOP) (A: Dec. 2023 )
=$1.05*42.9732
=$45.12

Quince Therapeutics's Market Cap for the quarter that ended in Sep. 2024 is calculated as

Market Cap (Q: Sep. 2024 )=Share Price (Q: Sep. 2024 )*Shares Outstanding (EOP) (Q: Sep. 2024 )
=$0.7762*43.2766
=$33.59

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Quince Therapeutics  (NAS:QNCX) Market Cap Explanation

Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the company’s debt. The real price you pay is the Enterprise Value.

Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.


Quince Therapeutics Market Cap Related Terms

Thank you for viewing the detailed overview of Quince Therapeutics's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.


Quince Therapeutics Business Description

Traded in Other Exchanges
N/A
Address
611 Gateway Boulevard, Suite 273, South San Francisco, CA, USA, 94080
Quince Therapeutics Inc is preclinical stage biopharmaceutical company focused on advancing innovative precision therapeutics for debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics.
Executives
Dirk Thye director, officer: Chief Executive Officer 6310 NANCY RIDGE DRIVE, SAN DIEGO CA 92121
Brendan Hannah officer: Chief Business Officer 269 EAST GRAND AVE, SOUTH SAN FRANCISCO CA 94080
Charles S. Ryan officer: President C/O APPLIED DNA SCIENCES, INC., 50 HEALTH SCIENCES DRIVE, STONY BROOK NY 11790
David Lamond director C/O CORTEXYME, INC., 269 EAST GRAND AVE., SOUTH SAN FRANCISCO CA 94080
Guenter Janhofer officer: Chief Scientific Officer 601 GATEWAY BOULEVARD, SUITE 1250, SOUTH SAN FRANCISCO CA 94080
Luca Benatti director C/O INTERCEPT PHARMACEUTICALS, INC., 450 WEST 15TH STREET, SUITE 505, NEW YORK NY 10011
Margaret Mcloughlin director C/O CORTEXYME, INC., 269 EAST GRAND AVE., SOUTH SAN FRANCISCO CA 94080
Ted Monohon officer: Chief Accounting Officer C/O FANTEX, INC., 330 TOWNSEND ST., SUITE 234, SAN FRANCISCO CA 94107
June Bray director C/O BIOXCEL THERAPEUTICS, INC., 555 LONG WHARF DRIVE, NEW HAVEN CT 06511
Caryn Gordon Mcdowell officer: Chief Legal & Adm. Officer 280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Philip S Low director 3000 KENT AVE STE A1-100, WEST LAFAYETTE IN 47906
Karen L. Smith officer: Chief Medical Officer C/O JAZZ PHARMACEUTICALS PLC, 5TH FL, WATERLOO EXCHANGE, WATERLOO RD, DUBLIN L2 4 L2
Marwan Sabbagh director C/O CORTEXYME, INC., 269 EAST GRAND AVE., SOUTH SAN FRANCISCO CA 94080
Stephen S. Dominy director, officer: Chief Scientific Officer C/O CORTEXYME, INC., 269 EAST GRAND AVE., SOUTH SAN FRANCISCO CA 94105
Christopher P. Lowe officer: Chief Financial Officer 2511 N LOOP 1604,, SUITE 204, SAN ANTONIO TX 78258